Japan Dry Eye Disease Market Forecast 2024-2032

Japan Dry Eye Disease Market Forecast 2024-2032

The Japan dry eye disease market is projected to grow at a CAGR of 5.26% from 2024 to 2032. The market was valued at $251.44 million in 2023, reaching an expected revenue of $401.68 million by 2032. The rising prevalence of dry eye diseases in Japan is linked to modern lifestyle factors such as increased screen exposure and environmental pollution, which significantly contribute to the incidence of dry eye disease symptoms. The growing geriatric population also plays a key role, as older individuals are more susceptible to dry eye diseases due to age-related reduction in tear production.

MARKET INSIGHTS

Rising awareness about dry eye disease and its symptoms, coupled with improved access to treatments, has significantly expanded the market in Japan. The growing prevalence of chronic conditions such as diabetes and autoimmune disorders, which are known causes of dry eye disease, has also increased the patient base. Furthermore, two cross-sectional, population-based studies evaluated the epidemiology of dry eye disease (DED) in Japan and found that its prevalence in the Japanese population was higher compared to other countries.

The most commonly prescribed treatments for dry eye in Japan are the 3% diquafosol ophthalmic solution (Diquas; Santen Pharmaceutical Co., Ltd, Osaka, Japan), available since 2010, which directly stimulates aqueous and mucous secretion on the ocular surface, and the 2% rebamipide ophthalmic suspension (Mucosta; Otsuka Pharmaceutical Co Ltd, Tokyo, Japan), available since 2012.

Furthermore, according to a study titled ‘Medical Treatment for Dry Eye in Japan, ’ sodium hyaluronate ophthalmic solutions have been used for many years in combination with preservative-free artificial tear solutions to treat dry eyes. The same study also highlighted the economic burden associated with DED in Japan, estimating the annual health plan cost per patient at $323.

Additionally, productivity losses per patient due to DED ranged from $741 to $6,160, underscoring the significant economic impact of the condition across generations in the Japanese population. This economic burden further drives the market’s growth, as it emphasizes the need for effective treatment options. Additional factors such as technological advancements, research and development efforts, government initiatives, and the growing prevalence of dry eye disease are expected to propel the market in Japan. As a result, the market is anticipated to grow significantly throughout the forecast period.

SEGMENTATION ANALYSIS

The Japan dry eye disease market segmentation includes distribution channel, type, dosage, and product. The dosage segment is further classified into eye drops, eye solutions, ointments, gels, and capsules & tablets.

Eye drops are the most commonly used and effective dosage type for managing and treating dry eye disease. They provide localized relief by directly targeting the ocular surface, delivering hydration, and mimicking natural tears to alleviate symptoms such as irritation, redness, and dryness. Eye drops are available in various formulations, including artificial tears, anti-inflammatory agents, and lubricating gels, to cater to different levels of dry eye severity.

Some eye drops contain active ingredients like sodium hyaluronate, which enhances moisture retention, or ciclosporin, which reduces inflammation and promotes tear production. Preservative-free options are also available to minimize potential irritation, especially for patients with sensitive eyes or those requiring frequent use. Eye drops are convenient, easy to administer, and widely accessible over-the-counter (OTC) or through prescriptions for more specialized formulations. This flexibility and variety make them an essential and preferred treatment method for dry eye disease, suitable for both acute and chronic management.

COMPETITIVE INSIGHTS

Some of the leading companies in the Japan dry eye disease market include Bausch Health Companies Inc, Otsuka Pharmaceutical Co Ltd, Allergan Plc (Acquired by AbbVie), etc.

Otsuka Pharmaceutical Co Ltd operates across various sectors, including pharmaceuticals, nutraceuticals, and consumer products, through its subsidiaries. The company focuses on the development, manufacturing, and sale of medicines for a wide range of conditions, including cancer, ophthalmic diseases, infectious diseases, gastrointestinal and respiratory conditions, and allergies. Its diverse product portfolio encompasses functional foods and beverages, pharmaceutical products, over-the-counter (OTC) items, electronic equipment, and fine chemicals.

Otsuka markets its products across Asia, Europe, and North America, with its headquarters located in Chiyoda-ku, Tokyo, Japan. One of its key products, Mucosta Ophthalmic Suspension, is designed to stabilize the tear film, making it an effective treatment for dry eye disease.KEY FINDINGS The Japan dry eye disease market is projected to grow at a CAGR of 5.26% from 2024 to 2032. The market was valued at $251.44 million in 2023, reaching an expected revenue of $401.68 million by 2032. The rising prevalence of dry eye diseases in Japan is linked to modern lifestyle factors such as increased screen exposure and environmental pollution, which significantly contribute to the incidence of dry eye disease symptoms. The growing geriatric population also plays a key role, as older individuals are more susceptible to dry eye diseases due to age-related reduction in tear production. MARKET INSIGHTS Rising awareness about dry eye disease and its symptoms, coupled with improved access to treatments, has significantly expanded the market in Japan. The growing prevalence of chronic conditions such as diabetes and autoimmune disorders, which are known causes of dry eye disease, has also increased the patient base. Furthermore, two cross-sectional, population-based studies evaluated the epidemiology of dry eye disease (DED) in Japan and found that its prevalence in the Japanese population was higher compared to other countries. The most commonly prescribed treatments for dry eye in Japan are the 3% diquafosol ophthalmic solution (Diquas; Santen Pharmaceutical Co., Ltd, Osaka, Japan), available since 2010, which directly stimulates aqueous and mucous secretion on the ocular surface, and the 2% rebamipide ophthalmic suspension (Mucosta; Otsuka Pharmaceutical Co Ltd, Tokyo, Japan), available since 2012. Furthermore, according to a study titled ‘Medical Treatment for Dry Eye in Japan, ’ sodium hyaluronate ophthalmic solutions have been used for many years in combination with preservative-free artificial tear solutions to treat dry eyes. The same study also highlighted the economic burden associated with DED in Japan, estimating the annual health plan cost per patient at $323. Additionally, productivity losses per patient due to DED ranged from $741 to $6,160, underscoring the significant economic impact of the condition across generations in the Japanese population. This economic burden further drives the market’s growth, as it emphasizes the need for effective treatment options. Additional factors such as technological advancements, research and development efforts, government initiatives, and the growing prevalence of dry eye disease are expected to propel the market in Japan. As a result, the market is anticipated to grow significantly throughout the forecast period. SEGMENTATION ANALYSIS The Japan dry eye disease market segmentation includes distribution channel, type, dosage, and product. The dosage segment is further classified into eye drops, eye solutions, ointments, gels, and capsules & tablets. Eye drops are the most commonly used and effective dosage type for managing and treating dry eye disease. They provide localized relief by directly targeting the ocular surface, delivering hydration, and mimicking natural tears to alleviate symptoms such as irritation, redness, and dryness. Eye drops are available in various formulations, including artificial tears, anti-inflammatory agents, and lubricating gels, to cater to different levels of dry eye severity. Some eye drops contain active ingredients like sodium hyaluronate, which enhances moisture retention, or ciclosporin, which reduces inflammation and promotes tear production. Preservative-free options are also available to minimize potential irritation, especially for patients with sensitive eyes or those requiring frequent use. Eye drops are convenient, easy to administer, and widely accessible over-the-counter (OTC) or through prescriptions for more specialized formulations. This flexibility and variety make them an essential and preferred treatment method for dry eye disease, suitable for both acute and chronic management. COMPETITIVE INSIGHTS Some of the leading companies in the Japan dry eye disease market include Bausch Health Companies Inc, Otsuka Pharmaceutical Co Ltd, Allergan Plc (Acquired by AbbVie), etc. Otsuka Pharmaceutical Co Ltd operates across various sectors, including pharmaceuticals, nutraceuticals, and consumer products, through its subsidiaries. The company focuses on the development, manufacturing, and sale of medicines for a wide range of conditions, including cancer, ophthalmic diseases, infectious diseases, gastrointestinal and respiratory conditions, and allergies. Its diverse product portfolio encompasses functional foods and beverages, pharmaceutical products, over-the-counter (OTC) items, electronic equipment, and fine chemicals. Otsuka markets its products across Asia, Europe, and North America, with its headquarters located in Chiyoda-ku, Tokyo, Japan. One of its key products, Mucosta Ophthalmic Suspension, is designed to stabilize the tear film, making it an effective treatment for dry eye disease.

Please Note: Report delivered with PDF + Excel